Changes in the Incidence of Endstage Renal Disease Due to Lupus Nephritis in the United States, 1996-2004

被引:87
作者
Ward, Michael M. [1 ]
机构
[1] NIAMSD, Intramural Res Program, NIH, US Dept HHS, Bethesda, MD 20892 USA
基金
美国国家卫生研究院;
关键词
SYSTEMIC LUPUS ERYTHEMATOSUS; LUPUS NEPHRITIS; ENDSTAGE RENAL DISEASE; INCIDENCE;
D O I
10.3899/jrheum.080625
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. To determine if the incidence of endstage renal disease (ESRD) due to lupus nephritis has decreased from 1996 to 2004. Methods. Patients age 15 years or older with incident ESRD due to lupus nephritis in 1996-2004 and living in one of the 50 United States or the District Of Columbia were identified using the US Renal Data System, a national population-based registry of all patients receiving renal replacement therapy for ESRD. Incidence rates were computed for each calendar year, using population estimates of the US census as denominators. Results. Over the 9-year study period, 9199 new cases of ESRD due to lupus nephritis were observed. Incidence rates, adjusted to the age, sex, and race composition of the US population in 2000, were 4.4 per million in 1996 and 4.9 per million in 2004. Compared to the pooled incidence rate in 1996-1998, the relative risk of ESRD due to lupus nephritis in 1999-2000 was 0.99 (95% CI 0.93-1.06). in 2001-2002 was 0.99 (95% CI 0.92-1.06), and in 2003-2004 was 0.96 (95%, CI 0.89-1.02). Findings were similar in analyses stratified by sex, age group, race, and socioeconomic status. Conclusion. There was no decrease in the incidence of ESRD due to lupus nephritis between 1996 and 2004. This may reflect the limits of effectiveness Of Current treatments, or limitations in access. use, or adherence to treatment. (First Release Nov 1 2008; J Rheumatol 2009;36:63-67; doi: 10.3999/jrheum.090625)
引用
收藏
页码:63 / 67
页数:5
相关论文
共 13 条
  • [1] Bruce IN, 2000, ARTHRIT CARE RES, V13, P406, DOI 10.1002/1529-0131(200012)13:6<406::AID-ART11>3.3.CO
  • [2] 2-U
  • [3] Prevalence and predictors of highly active antiretroviral therapy use in patients with HIV infection in the United States
    Cunningham, WE
    Markson, LE
    Andersen, RM
    Crystal, SH
    Fleishman, JA
    Golin, C
    Gifford, A
    Liu, HHH
    Nakazono, TT
    Morton, S
    Bozzette, SA
    Shapiro, MF
    Wenger, NS
    [J]. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2000, 25 (02) : 115 - 123
  • [4] Faurschou M, 2006, J RHEUMATOL, V33, P1563
  • [5] Improved clinical outcome of lupus nephritis during the past decade: importance of early diagnosis and treatment
    Fiehn, C
    Hajjar, Y
    Mueller, K
    Waldherr, R
    Ho, AD
    Andrassy, K
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 (05) : 435 - 439
  • [6] Current management of lupus nephritis: popular misconceptions
    Jayne, D.
    [J]. LUPUS, 2007, 16 (03) : 217 - 220
  • [7] Care in US hospitals - The Hospital Quality Alliance Program.
    Jha, AK
    Li, ZH
    Orav, EJ
    Epstein, AM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (03) : 265 - 274
  • [8] Association between hospital process performance and outcomes among patients with acute coronary syndromes
    Peterson, ED
    Roe, MT
    Mulgund, J
    DeLong, ER
    Lytle, BL
    Brindis, RG
    Smith, SC
    Pollack, CV
    Newby, LK
    Harrington, RA
    Gibler, WB
    Ohman, EM
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (16): : 1912 - 1920
  • [9] Applying clinical epidemiological methods to health equity: the equity effectiveness loop
    Tugwell, P
    de Savigny, D
    Hawker, G
    Robinson, V
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2006, 332 (7537): : 358 - 361
  • [10] *US REN DAT SYST, 2005, USRDS 2005 ANN REP A